drugset / Trial / NCT02183298
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Doses of BI 1356 BS in Healthy Male Volunteers
RandomizedSingle-groupSingle-blindTreatment
Summary
Study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of BI 1356 as formulation for intravenous administration
Timeline
- Start
- 2006-05
- Primary completion
- 2006-07
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Linagliptin | Unknown | 0.5 mg | — |
| Subject | Linagliptin | Unknown | 5 mg | — |
| Subject | Linagliptin | Unknown | 10 mg | — |
Indications
No indication recorded.